Hyperandrogenism

Women with vs. without polycystic ovary syndrome have a higher risk for emotional and uncontrolled eating behaviors at midlife, with contrasts observed among different phenotypes, according to findings published in Fertility and Sterility.

DENVER — For women with polycystic ovary syndrome and overweight or obesity, neither oral contraceptive pills nor metformin altered the characteristic markers of metabolic syndrome, either alone or in combination, researchers reported.

Hormonal dysregulation seen in polycystic ovary syndrome can cause a cascade of issues for women, from hirsutism and weight gain to subfertility and type 2 diabetes. Yet beyond the reproductive years, the condition is often ignored.

Women with polycystic ovary syndrome and high androgen levels may have a higher risk for liver disease than those with PCOS and normal androgen levels, according to an analysis of UK Biobank data.

BOSTON — Evidence suggests hyperandrogenism is associated with changes in the gut microbiome in women with polycystic ovary syndrome and the gut microbiome may play a causal role in PCOS metabolic dysregulation, according to a speaker.

Childhood adiposity could predict future polycystic ovary syndrome in girls, according to a study published in Pediatrics.

Magnesium supplementation for 10 weeks led to no beneficial effects for women with polycystic ovary syndrome experiencing hyperandrogenism, hirsutism and impaired sleep quality, researchers reported in Health Science Reports.

Polycystic ovary syndrome is a common endocrine disorder affecting reproductive-age women, yet the complexity and heterogeneity of PCOS have confounded researchers attempting to understand its long-term consequences.

The hyperandrogenic phenotype of polycystic ovary syndrome is the one most closely related to the things we think are “bad” for cardiovascular disease — obesity, insulin resistance — and those seem to be the driving factors of CVD risk. We also see examples of elevated CV risk in the setting of higher androgen levels in postmenopausal women and transgender men prescribed gender-affirming hormone therapy.

Women with a high genetic risk score for hyperandrogenism have a higher bone mineral density and a lower risk for fracture than those with a lower risk score, according to study results published in Bone.